FLUNEXT transcriptome analysis

Influenza virus infections remain a major public health burden. The intrinsic ever-evolving nature of this virus, the suboptimal efficacy of recent influenza inactivated vaccines, as well as the emergence of resistance against a limited antiviral arsenal, highlight the urgent need for novel therapeutic approaches to treat influenza infections. Here, we exploited in vivo transcriptomic signatures of infection, directly obtained from a patient’s cohort to identify in silico a list of marketed drugs with signatures that counteracted that of the infection state. Nasal swabs were collected from patients infected with influenza H1N1 virus, either at inclusion (before any antiviral treatment, Infected status), or 3 month after recovery (Cured status). Total RNA was extracted from nasal swabs collected into RNAlater buffer, and subsequently analyzed by microarray.